Medscape1d
Neuropathy in Parkinson’s Disease May Be Related to L-Dopa Exposure
Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market ...
News Medical23d
Wearables and machine learning predict five-year fall risk in Parkinson’s patients
The participants were recruited based on specific criteria, including mild-to-moderate idiopathic Parkinson's disease and the ability to walk and stand unassisted. Baseline data were collected ...
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
The Company has received approval to begin enrollment of the Phase 1b clinical trial in AustraliaPhase 1b clinical trial will assess safety and ...
Pharmaceutical Technology2d
Human Amniotic Epithelial Stem Cells by ICELL Biotechnology for Parkinson’s Disease: Likelihood of Approval
Human Amniotic Epithelial Stem Cells is under clinical development by iCELL Biotechnology and currently in Phase I for Parkinson's Disease.
Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...
Science Daily9d
Propranolol reduces tremors in Parkinson's disease
The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into ...
Yahoo Finance9d
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
Gain will be working with local Parkinson’s disease (PD) advocacy groups to support enrollment and expects enrollment to complete in the spring of 2025 with data from the study expected mid-2025.